Company intelligence / Profile preview

Philikos BV

Nijmegen, Gelderland, Netherlandsfacebook.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Philikos is developing T‑Guard, a combination of two toxin-conjugated antibodies designed to transiently deplete overactive T and NK cells in patients with systemic sclerosis. This approach aims to reset the immune system more safely than autologous stem cell transplantation. The drug is entering clinical evaluation, with recent funding secured for patient studies. No published clinical results yet.

Therapeutic areas: RheumatologyImmunology
Modalities: Toxin-conjugated antibodiesBiologics (antibody-based therapy)
Industry: Biotech

Drug pipeline

1 asset

grisnilimab setaritox

Unknown

Partnerships

Radboud university medical center (Radboudumc)Health Holland (grant provider)Biotech Booster (grant provider)Oost NL and Essential Investments provided convertible loans/funding support

Beyond the preview

Go deeper on Philikos BV.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Philikos BV.

Explore the full profile